Showing 1 - 10 of 706
Optimal management of human immunodeficiency virus type 1 (HIV-1)-infected children requires a commitment from the healthcare delivery system, healthcare providers, and affected families and caregivers. When adequate resources are available (as in most industrialised nations), an aggressive...
Persistent link: https://www.econbiz.de/10005448902
Objective: To describe the use of hospital and community services for children infected with HIV and estimate the cost per patient-year by stage of HIV infection during the era of antiretroviral monotherapy. Design: Data on the use of hospital services were collected from case notes; the use of...
Persistent link: https://www.econbiz.de/10005449015
This study assessed the willingness of parents to pay for a reduction in the postoperative emesis experienced by children. The willingness-to-pay technique was used to value the intangible benefits, such as relief from anxiety and discomfort, resulting from a reduction in postoperative emesis in...
Persistent link: https://www.econbiz.de/10005449231
Until recently, control of influenza has focused on increasing the use of the inactivated influenza vaccine and, in some countries, encouraging the appropriate use of the antiviral drugs amantadine and rimantadine. Now that a new class of antiviral drugs, the neuraminidase inhibitors, has been...
Persistent link: https://www.econbiz.de/10005404670
Background:Background: Underuse of controller therapy among Medicaid-enrolled children is common and leads to more emergency department (ED) visits and hospitalizations. However, there is little evidence about the relationship between medication adherence, outcomes and costs once controller...
Persistent link: https://www.econbiz.de/10010541097
Background: The Food and Drug Administration Modernization Act (FDAMA) of 1997, Best Pharmaceuticals for Children Act (BPCA) of 2002 and Pediatric Research Equity Act of 2007 provide an extended period of 6 months of marketing exclusivity (i.e. patent extension) to prescription drug...
Persistent link: https://www.econbiz.de/10010614273
Objective: To determine the impact of respiratory syncytial virus (RSV) infection on healthcare resource use and costs in the US from the third-party payer perspective. Design: The study retrospectively analysed cross-sectional medical encounter data from three federally funded databases that...
Persistent link: https://www.econbiz.de/10005449224
Background: Vaccinating children against influenza virus may reduce infections in immunised children and household contacts, thereby reducing the household-based cost associated with respiratory illnesses. Objective: To evaluate the impact of influenza virus vaccination of daycare children on...
Persistent link: https://www.econbiz.de/10005404931
Screening programs for sickle cell disease, when effective, can reduce morbidity and mortality as a direct consequence of patient education and optimized clinical management. However, informed patient or parental consent is necessary prior to the screening process as a person's sickle status is...
Persistent link: https://www.econbiz.de/10005242993
Objective: To estimate the pharmacoeconomic impact for the French Social Security System of preventing recurrent acute rhinopharyngitis (RARP) in at-risk children with OM-85 BV, an immunostimulating agent indicated for the prevention of recurrences. Design: A decision-analysis model. The...
Persistent link: https://www.econbiz.de/10005243125